Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines
Cancers · 25.03.2026 · 18 (7) · 1066
DOI: 10.3390/cancers18071066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.03.2026. Verfasst von Marina Antonacci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian foundations Fondazione GAIA, Heal Foundation, Onlus Mia Neri Foundation.
Abstract (Originalsprache)
Tyrosine kinases (TKs) are drug targets in diffuse intrinsic pontine glioma (DIPG). Ion channels are emerging targets in cancer. TKIs targeting different kinases such as everolimus, crizotinib, dasatinib, erlotinib, lapatinib, perifosine and midostaurin (0.001–100 μM) were investigated on cell proliferation and ion channel currents.
Methods
Cell viability assays in parallel with a patch-clamp study and Western blot of target proteins are performed in SU-DIPG-36 and SU-DIPG-50 cells.
Results
Midostaurin is the most effective drug in different assays. Patch-clamp investigations show that the application of midostaurin reduced the inward and outward whole-cell cation channel currents vs. controls in the presence of low internal ATP. These currents were sensitive to the KATP channel inhibitors glibenclamide and repaglinide and were fully reduced by the unselective blocker TEA-BaCl2. Midostaurin also reduced currents that are sensitive to TRPV1 channel blockers capsazepine and ruthenium-red. The IC50 values of midostaurin as an antiproliferative drug and ion channel inhibitor in either cell line are in the sub-micromolar range. In SU-DIPG-36 cells midostaurin causes a concentration-dependent upregulation of autophagy markers.
Conclusions
The inhibition of cation channel currents by midostaurin in SU-DIPG-36 and SU-DIPG-50 cells and the autophagy potentiation in SU-DIPG-36 cells can be novel mechanisms in DIPG.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology Saverio de Bellis, Istituti di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Research Hospital, 70013 Castellana Grotte…
ORCID-Profile: Annamaria Di Turi, Morena Miciaccia, Maria Grazia Perrone, Antonio Scilimati, Domenico Tricarico
Förderung
- Italian foundations Fondazione GAIA
- Heal Foundation
- Onlus Mia Neri Foundation
- Matibellula Foundation
Zitieren
APA
Antonacci, M., Di Turi, A., Miciaccia, M., Denora, M., Maqoud, F., Perrone, M. G., Scilimati, A., & Tricarico, D. (2026). Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines. Cancers, 18(7), 1066. https://doi.org/10.3390/cancers18071066
Vancouver
Antonacci M, Di Turi A, Miciaccia M, Denora M, Maqoud F, Perrone MG, et al. Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines. Cancers. 2026;18(7):1066. doi:10.3390/cancers18071066
BibTeX
@article{Antonacci2026,
author = {Antonacci, Marina and Di Turi, Annamaria and Miciaccia, Morena and Denora, Michele and Maqoud, Fatima and Perrone, Maria Grazia and Scilimati, Antonio and Tricarico, Domenico},
title = {Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1066},
doi = {10.3390/cancers18071066}
}
EUVIMED